<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794911</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000171</org_study_id>
    <nct_id>NCT00794911</nct_id>
    <nct_alias>NCT00794937</nct_alias>
  </id_info>
  <brief_title>Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation</brief_title>
  <official_title>Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether psychological intervention is&#xD;
      effective in improving quality of life, mood, and relationships among adults with hepatitis C&#xD;
      virus and cirrhosis awaiting liver transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of life (QOL) outcomes are important to all stakeholders in liver transplantation.&#xD;
      For patients with end-stage liver disease, QOL is significantly compromised and more data&#xD;
      about QOL allows them to make an informed risk-benefit analysis in deciding whether to pursue&#xD;
      transplantation. The long-term goal of this research program is to better understand how QOL&#xD;
      can be enhanced, to identify the mechanisms underlying QOL changes, to identify which&#xD;
      patients benefit most from QOL intervention, and to determine whether QOL benefits can extend&#xD;
      beyond transplantation. The objective of this research is to determine the effectiveness,&#xD;
      feasibility and applicability of Quality of Life Therapy (QOLT) in treating adults with&#xD;
      hepatitis C virus and cirrhosis awaiting liver transplantation. In a recent small,&#xD;
      single-center clinical trial, we demonstrated that QOLT can improve QOL, psychological&#xD;
      functioning, and social intimacy in patients awaiting lung transplantation. We now seek to&#xD;
      examine whether this intervention can be effectively adapted and implemented with adults with&#xD;
      hepatitis C virus and cirrhosis awaiting liver transplantation. The central hypothesis is&#xD;
      that by targeting improvements in specific life domains, QOLT yields significant clinical&#xD;
      benefits in QOL, psychological functioning, and the patient-caregiver relationship. This&#xD;
      hypothesis is being tested by pursuing three specific aims: 1) Determine the effectiveness of&#xD;
      QOLT; 2) Examine the differential effectiveness of QOLT by race (White, African American);&#xD;
      and 3) Assess the feasibility of a multisite R01 application. Under the first aim, adults&#xD;
      with hepatitis C virus and cirrhosis awaiting liver transplantation are being randomized to&#xD;
      receive QOLT, Supportive Therapy (ST), or Standard Care (SC). Primary outcomes are changes in&#xD;
      QOL, psychological functioning, and social intimacy at 1 and 12 weeks post-treatment. Under&#xD;
      the second aim, the relationship between race and intervention outcomes will be closely&#xD;
      examined. Under the third aim, attrition rates, reasons for attrition, therapist adherence to&#xD;
      treatment protocols, and participant satisfaction ratings are being gathered to assess the&#xD;
      need for protocol changes prior to developing a larger, multisite clinical trial R01&#xD;
      application. This study is innovative because it is among the first to evaluate a&#xD;
      theoretically-driven psychological intervention to specifically improve QOL in the context of&#xD;
      hepatitis C virus and cirrhosis and liver transplantation. The research is significant&#xD;
      because it is expected to advance and expand understanding of how QOL can be improved in&#xD;
      patients with hepatitis C virus and cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on the following measures at 12 weeks post-intervention: Quality of Life Inventory, SF-36, Liver Disease Quality of Life instrument, CDC's Activity Limitations Module HRQoL-14, Hopkins Symptom Checklist-25, POMS, and Miller Social Intimacy Scale.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Chronic HCV</condition>
  <arm_group>
    <arm_group_label>QOLT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supportive Therapy (ST) 8 weekly individual counseling sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Therapy</intervention_name>
    <description>8 weekly individual counseling sessions</description>
    <arm_group_label>QOLT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supportive Therapy</intervention_name>
    <description>8 weekly individual counseling sessions</description>
    <arm_group_label>ST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between 21 and 70 years of age&#xD;
&#xD;
          -  Diagnosis of chronic HCV&#xD;
&#xD;
          -  Wait-listed for liver transplantation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Primary caregiver identified as spouse or domestic partner&#xD;
&#xD;
          -  Resides within 60 minutes of transplant center&#xD;
&#xD;
          -  MELD score &lt; 20&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior recipient of liver transplantation&#xD;
&#xD;
          -  Prior recipient of other solid organ transplantation&#xD;
&#xD;
          -  Wait-listed for combined liver-kidney transplantation&#xD;
&#xD;
          -  Current substance abuse or dependency&#xD;
&#xD;
          -  Currently hospitalized&#xD;
&#xD;
          -  Sustained (2 or more consecutive months) MELD score less than or equal to 20&#xD;
&#xD;
          -  Current recipient of psychological intervention services&#xD;
&#xD;
          -  Substantial cognitive impairment (score of 23 or less on the Mini-Mental State&#xD;
             Examination)&#xD;
&#xD;
          -  Communication difficulties (speech, hearing) so substantial that they would prevent&#xD;
             patient from participating actively in one of the interventions (determined by&#xD;
             interviewer rating)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Rodrigue, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>James Rodrigue</investigator_full_name>
    <investigator_title>Professor of Psychology in the Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Chronic HCV</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

